Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for CLL: Eradication of Specific FISH Abnormalities with Relation to Gvhd and Transplant Outcomes.

Cynthia Toze, MD, FRCPC, Chinmay B. Dalal, MD, Tanya L. Gillan, PhD, FCCMG, Thomas J. Nevill, MD, FRCPC, Michael J. Barnett, BMBS, Stephen H. Nantel, MD, FRCPC, Donna E. Hogge, MD, PhD, Donna L. Forrest, MD, Heather Sutherland, MD, PhD, FRCPC, Kevin Song, MD, Raewyn Broady, MBChB, FRACP, Maryse Power, MD, FRCPath, Sujaatha Narayanan, MD, Clayton A. Smith, MD, FRCPC, John Shepherd

Blood (2010) 116 (21): 3465.

https://doi.org/10.1182/blood.V116.21.3465.3465

Published: 2010

Journal Articles

Gemcitabine, Dexamethasone, and Cisplatin (GDP) Is An Effective and Well-Tolerated out-Patient Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL)

Alden A. Moccia, Felicitas Hitz, Paul Hoskins, Richard Klasa, Maryse Power, Kerry J. Savage, Tamara Shenkier, John Shepherd, Brian Skinnider, Graham W. Slack, Kevin Song, Randy D. Gascoyne, Joseph M. Connors, Laurie Sehn

Blood (2010) 116 (21): 113.

https://doi.org/10.1182/blood.V116.21.113.113

Published: 2010

Journal Articles

The Use of Novel Agents In Patients with Multiple Myeloma Initially Treated with Allogeneic Stem Cell Transplantation Results In A Significant Prolongation of Post Relapse Survival.

Christopher P. Venner, MD, Heather Sutherland, MD, PhD, FRCPC, John Shepherd, MD, FRCPC, Yasser Abou Mourad, MD, Michael J. Barnett, BMBS, Donna L. Forrest, MD, Donna E. Hogge, MD, PhD, Stephen H. Nantel, MD, FRCPC, Sujaatha Narayanan, MD, Thomas J. Nevill, MD, FRCPC, Janet Nitta, Maryse Power, MD, FRCPath, Cynthia Toze, MD, FRCPC, Clayton Smith, Kevin Song, MD

Blood (2010) 116 (21): 4580.

https://doi.org/10.1182/blood.V116.21.4580.4580

Published: 2010

Journal Articles

High Dose Melphalan and Autologous Stem Cell Transplantation In Light Chain and Light and Heavy Chain Deposition Disease: Hematologic and Renal Outcomes.

David Telio, MD, John Shepherd, Donna L. Forrest, MD, Michael J. Barnett, BMBS, Thomas J. Nevill, MD, FRCPC, Leslie Zypchen, MD, Kevin Song, MD

Blood (2010) 116 (21): 4597.

https://doi.org/10.1182/blood.V116.21.4597.4597

Published: 2010

Journal Articles

Induction Therapy with High-Dose Dex Alone in Newly Diagnosed Myeloma Patients Produces a 57% Partial Response and Is Predictive of Progression Free Survival.

David A. Irvine, Michael J. Barnett, Ryan Brinkman, Donna L. Forrest, Donna E. Hogge, Julye Lavoie, Linda Lei, Stephen H. Nantel, Thomas J. Nevill, Janet Nitta, John Shepherd, Kevin Song, Cynthia Toze, Heather Sutherland

Blood (2006) 108 (11): 3098.

https://doi.org/10.1182/blood.V108.11.3098.3098

Published: 2006

Journal Articles

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

Bronno van der Holt, Bob Löwenberg, Alan K. Burnett, Wolfgang U. Knauf, John Shepherd, Pier Paolo Piccaluga, Gert J. Ossenkoppele, Gregor E. G. Verhoef, Augustin Ferrant, Michael Crump, Dominik Selleslag, Matthias Theobald, Martin F. Fey, Edo Vellenga, Margaret Dugan, Pieter Sonneveld, on behalf of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and the United Kingdom Medical Research Council (MRC)

Blood (2005) 106 (8): 2646–2654.

https://doi.org/10.1182/blood-2005-04-1395

Published: 2005

NARROW

Allogeneic Hematopoietic Stem Cell Transplantation for CLL: Eradication of Specific FISH Abnormalities with Relation to Gvhd and Transplant Outcomes.

Gemcitabine, Dexamethasone, and Cisplatin (GDP) Is An Effective and Well-Tolerated out-Patient Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL)

The Use of Novel Agents In Patients with Multiple Myeloma Initially Treated with Allogeneic Stem Cell Transplantation Results In A Significant Prolongation of Post Relapse Survival.

High Dose Melphalan and Autologous Stem Cell Transplantation In Light Chain and Light and Heavy Chain Deposition Disease: Hematologic and Renal Outcomes.

Induction Therapy with High-Dose Dex Alone in Newly Diagnosed Myeloma Patients Produces a 57% Partial Response and Is Predictive of Progression Free Survival.

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

Email alerts

ASH Publications

American Society of Hematology

Allogeneic Hematopoietic Stem Cell Transplantation for CLL: Eradication of Specific FISH Abnormalities with Relation to Gvhd and Transplant Outcomes.

Gemcitabine, Dexamethasone, and Cisplatin (GDP) Is An Effective and Well-Tolerated out-Patient Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL)

The Use of Novel Agents In Patients with Multiple Myeloma Initially Treated with Allogeneic Stem Cell Transplantation Results In A Significant Prolongation of Post Relapse Survival.

High Dose Melphalan and Autologous Stem Cell Transplantation In Light Chain and Light and Heavy Chain Deposition Disease: Hematologic and Renal Outcomes.

Induction Therapy with High-Dose Dex Alone in Newly Diagnosed Myeloma Patients Produces a 57% Partial Response and Is Predictive of Progression Free Survival.

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only